103 related articles for article (PubMed ID: 8552890)
1. Two-sample rank tests for acceleration in cure models.
Lee JW
Stat Med; 1995 Oct; 14(19):2111-8. PubMed ID: 8552890
[TBL] [Abstract][Full Text] [Related]
2. Cure model analysis in cancer: an application to data from the Children's Cancer Group.
Sposto R
Stat Med; 2002 Jan; 21(2):293-312. PubMed ID: 11782066
[TBL] [Abstract][Full Text] [Related]
3. Two-sample statistics for testing the equality of survival functions against improper semi-parametric accelerated failure time alternatives: an application to the analysis of a breast cancer clinical trial.
Broët P; Tsodikov A; De Rycke Y; Moreau T
Lifetime Data Anal; 2004 Jun; 10(2):103-20. PubMed ID: 15293627
[TBL] [Abstract][Full Text] [Related]
4. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
5. Semiparametric accelerated failure time cure rate mixture models with competing risks.
Choi S; Zhu L; Huang X
Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
[TBL] [Abstract][Full Text] [Related]
6. Causal inference for time-to-event data with a cured subpopulation.
Wang Y; Deng Y; Zhou XH
Biometrics; 2024 Mar; 80(2):. PubMed ID: 38708764
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival after childhood acute lymphoblastic leukaemia: population-based trends in cure and relapse by clinical characteristics.
Smith L; Glaser AW; Kinsey SE; Greenwood DC; Chilton L; Moorman AV; Feltbower RG
Br J Haematol; 2018 Sep; 182(6):851-858. PubMed ID: 29808915
[TBL] [Abstract][Full Text] [Related]
8. Covariate adjustment for non-parametric tests for censored survival data.
Li Z
Stat Med; 2001 Jun; 20(12):1843-53. PubMed ID: 11406845
[TBL] [Abstract][Full Text] [Related]
9. Assessing the fit of parametric cure models.
Wileyto EP; Li Y; Chen J; Heitjan DF
Biostatistics; 2013 Apr; 14(2):340-50. PubMed ID: 23197383
[TBL] [Abstract][Full Text] [Related]
10. Checking a semiparametric additive risk model.
Gandy A; Jensen U
Lifetime Data Anal; 2005 Dec; 11(4):451-72. PubMed ID: 16328571
[TBL] [Abstract][Full Text] [Related]
11. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia.
Frost BM; Nygren P; Gustafsson G; Forestier E; Jonsson OG; Kanerva J; Nygaard R; Schmiegelow K; Larsson R; Lönnerholm G;
Br J Haematol; 2003 Aug; 122(3):376-85. PubMed ID: 12877664
[TBL] [Abstract][Full Text] [Related]
12. Relationships among tests for censored data.
Letón E; Zuluaga P
Biom J; 2005 Jun; 47(3):377-87. PubMed ID: 16053261
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
[TBL] [Abstract][Full Text] [Related]
14. Tests for equality of survival distributions against non-location alternatives.
Bagdonavicius VB; Levuliene RJ; Nikulin MS; Zdorova-Cheminade O
Lifetime Data Anal; 2004 Dec; 10(4):445-60. PubMed ID: 15690995
[TBL] [Abstract][Full Text] [Related]
15. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method.
Dwivedi AK; Mallawaarachchi I; Alvarado LA
Stat Med; 2017 Jun; 36(14):2187-2205. PubMed ID: 28276584
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
17. Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators.
Bernasconi DP; Rebora P; Iacobelli S; Valsecchi MG; Antolini L
Stat Med; 2016 Mar; 35(7):1032-48. PubMed ID: 26503800
[TBL] [Abstract][Full Text] [Related]
18. Model evaluation based on the negative predictive value for interval-censored survival outcomes.
Han S; Tsui KW; Andrei AC
Stat Methods Med Res; 2017 Apr; 26(2):661-673. PubMed ID: 25305195
[TBL] [Abstract][Full Text] [Related]
19. Generalized additive models for medical research.
Hastie T; Tibshirani R
Stat Methods Med Res; 1995 Sep; 4(3):187-96. PubMed ID: 8548102
[TBL] [Abstract][Full Text] [Related]
20. Non-parametric Bayesian approach to hazard regression: a case study with a large number of missing covariate values.
Arjas E; Liu L
Stat Med; 1996 Aug; 15(16):1757-70. PubMed ID: 8870158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
